RSLS_OUT_1 [2025-04-01 05:38:20 -0400] 2259 Bytes | 613 tokens | Cum: 613 tkns (7.66% of 8k)
==========================================================================

We're scouting for winners today. Its 5:38:20 AM on Tue Apr 01, 2025 -0400 and I'm looking at ReShape Lifesciences (RSLS) up to 0.7468 from 0.3605

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

Here's the first list of news for ReShape Lifesciences:

C1 - Mar-10-25 08:31AM - ReShape Lifesciences Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
C2 - Feb-25-25 08:31AM - ReShape Lifesciences Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band 2.0 FLEX
C3 - Feb-15-25 11:17PM - ReShape Lifesciences Announces Pricing of Upsized $6.0 Million Public Offering
C4 - Feb-03-25 08:31AM - ReShape Lifesciences Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology
C5 - Jan-13-25 08:31AM - ReShape Lifesciences Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
C6 - Nov-14-24 04:05PM - ReShape Lifesciences Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update
C7 - Nov-12-24 04:05PM - ReShape Lifesciences to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
C8 - Nov-12-24 04:05PM 08:31AM - ReShape Lifesciences Receives Health Canada Approval for its Next-Generation Lap-Band 2.0 FLEX

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on ReShape Lifesciences (RSLS)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

RSLS_OUT_3 [2025-04-01 05:38:24 -0400] 1103 Bytes | 333 tokens | Cum: 948 tkns (11.85% of 8k)
==========================================================================

Showing C1 (chunk 1 of 8): C1:
**ReShape Lifesciences Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology**
Date: Mar-10-25 08:31AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/10/3039737/0/en/ReShape-Lifesciences-Receives-Notice-of-Allowance-for-U-S-Patent-Related-to-Its-Proprietary-Diabetes-Neuromodulation-Technology.html

March 10, 2025 08:31 ET| Source:ReShape Lifesciences IncReShape Lifesciences Inc

IRVINE, Calif., March 10, 2025 (GLOBE NEWSWIRE) --ReShape Lifesciences®(Nasdaq: RSLS),the premier physician-led weight loss and metabolic health solutions company, today announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 17/046,677, entitled, “Simultaneous Multi-Site Vagus Nerve Modulation for Improved Glycemic Control System and Methods.”

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RSLS_OUT_5 [2025-04-01 05:38:25 -0400] 927 Bytes | 288 tokens | Cum: 1331 tkns (16.64% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-31T18:35:36Z - MOMO'S BREAKOUT BOARD : All time low ReShape Lifesciences Inc.......
A2 - 2025-03-26T19:27:52Z - BB's Stock Haven : ALL TIME LOW!! ReShape Lifesciences Inc......
A3 - 2025-03-26T15:22:06Z - RSLS stock touches 52-week low at $0.49 amid sharp annual decline By Investing.com...
A4 - 2025-03-23T22:59:44Z - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FNA, AVTE, RSLS on Behalf of Shareholders -...
A5 - 2025-03-21T15:49:34Z - Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

RSLS_OUT_7 [2025-04-01 05:38:29 -0400] 1098 Bytes | 492 tokens | Cum: 1825 tkns (22.81% of 8k)
==========================================================================

Showing A1 (chunk 1 of 6): A1:
**MOMO'S BREAKOUT BOARD : All time low ReShape Lifesciences Inc....**Date: 2025-03-31Source: {'uri': 'investorshub.advfn.com', 'dataType': 'news', 'title': 'Investors Hub'}URL: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175999045All time low

ReShape Lifesciences Inc. (RSLS) :0,3485 -9,93%

52 Week Range 0.3485 - 29

Shares Outstanding 3.31M

https://dilutiontracker.com/app/search/RSLS

Total Cash (mrq) 5.7M

Total Debt (mrq) 191k

Book Value Per Share (mrq) 2.11

mktcap : 1.15M

Mar 28, 2025 0.440

Mar 27, 2025 0.481

Mar 26, 2025 0.541

Mar 25, 2025 0.660

Mar 24, 2025 0.680

Mar 21, 2025 0.700

Mar 20, 2025 0.750

Mar 19, 2025 0.640

Mar 18, 2025 0.640

Mar 17, 2025 0.650

Mar 14, 2025 0.645

Mar 13, 2025 0.690

Mar 12, 2025 0.703

Mar 11, 2025 0.717

Mar 10, 2025 0.880

Mar 07, 2025 0.951

Mar 06, 2025 0.990

Mar 05, 2025 1.020

Mar 04, 2025 1.060

Mar 03, 20

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RSLS_OUT_9 [2025-04-01 05:38:30 -0400] 1031 Bytes | 315 tokens | Cum: 2270 tkns (28.38% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-23T22:59:00Z - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FNA, AVTE, RSLS on Behalf of Shareholders
B2 - 2025-02-16T04:17:00Z - ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering
B3 - 2025-01-13T13:31:00Z - ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
B4 - 2024-07-09T12:32:57Z - ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With ... - GlobeNewswire
B5 - 2024-05-30T10:54:00Z - Investing in AI Penny Stocks? 3 Top Tips
B6 - 2024-05-15T20:05:00Z - ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

RSLS_OUT_11 [2025-04-01 05:38:33 -0400] 752 Bytes | 221 tokens | Cum: 2493 tkns (31.16% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FNA, AVTE, RSLS on Behalf of Shareholders**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/23/3047509/0/en/SHAREHOLDER-INVESTIGATION-Halper-Sadeh-LLC-Investigates-FNA-AVTE-RSLS-on-Behalf-of-Shareholders.htmlHalper Sadeh LLC is investigating potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to the proposed acquisitions of Paragon 28, Aerovate Therapeutics, and ReShape Lifesciences.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RSLS_OUT_13 [2025-04-01 05:38:33 -0400] 1127 Bytes | 301 tokens | Cum: 2854 tkns (35.68% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-02-20 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On February 15, 2025, ReShape Lifesciences Inc. (the Company) entered into a Securities Purchase Agrmt (the Purchase Agrmt) with certain investors (the Investors) pursuant to which the Company agreed to issue and sel...

S2 - 2025-01-21 8-K Item 1.01 Entry into a Material Definitive Agrmt.

As previously disclosed, on October 16, 2024, ReShape Lifesciences Inc. (the Company) entered into a securities purchase agreement (the SPA) with Ascent Partners Fund LLC, an institutional investor (the Investor). Pursuant t...

S3 - 2024-12-27 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On December 19, 2024, ReShape Lifesciences Inc. (the Company) entered into an equity purchase agreement (the Purchase Agrmt) with a certain investor (the Investor), which provides that, upon the terms and subject to the ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

RSLS_OUT_15 [2025-04-01 05:38:39 -0400] 1098 Bytes | 299 tokens | Cum: 3155 tkns (39.44% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 1.01 Entry into a Material Definitive Agreement.

On February 15, 2025, ReShape Lifesciences Inc. (the Company) entered into a Securities Purchase Agreement (the Purchase Agreement) with certain investors (the Investors) pursuant to which the Company agreed to issue and sell to the Investors (i) 2,575,107 shares of the Companys common stock, par value $0.001 per share (the Common Stock) and (ii) warrants to purchase up to 2,575,107 shares of Common Stock at an initial exercise price of $5.83 per share (the Warrants), subject to adjustment as set forth in the Warrants. The securities were sold as part of units at a price of $2.33 per unit. The offering closed on February 18, 2025.

The Warrants, which are not exercisable unless and until approved by the Companys stockholders, will expire on the later of (i) 12 days after date of stockholder approval and (ii) the earlier of (x) t

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RSLS_OUT_17 [2025-04-01 05:38:51 -0400] 4170 Bytes | 1201 tokens | Cum: 4495 tkns (56.19% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+-----------------------+------------------------+
| Volume: 1,009,184 | Perf Month: -65.00% | Option/Short: No / No | Sales Y/Y TTM: -16.55% |
+--------------------+-----------------------+-----------------------+------------------------+
| Avg Volume: 1.19M | Perf Quarter: -92.41% | Short Float: 13.55% | ROE: -309.28% |
+--------------------+-----------------------+-----------------------+------------------------+
| Rel Volume: 0.85 | Index: - | Short Ratio: 0.31 | ROI: -451.85% |
+--------------------+-----------------------+-----------------------+------------------------+
| RSI (14): 17.86 | Market Cap: 1.19M | Short Interest: 0.37M | Sales Surprise: - |
+--------------------+-----------------------+-----------------------+------------------------+
| ATR (14): 0.14 | Shs Outstand: 3.31M | Beta: 1.60 | EPS Surprise: - |
+--------------------+-----------------------+-----------------------+------------------------+
| SMA20: -45.85% | Shs Float: 2.71M | Sales Q/Q: 6.36% | P/E: - |
+--------------------+-----------------------+-----------------------+------------------------+
| SMA50: -81.28% | Inst Own: 1.01% | Sales past 5Y: 56.15% | Earnings: Nov 14 AMC |
+--------------------+-----------------------+-----------------------+------------------------+
| SMA200: -94.32% | Insider Own: 18.08% | Employees: - | |
+--------------------+-----------------------+-----------------------+------------------------+
| Perf Week: -44.37% | Insider Trans: 0.00% | Debt/Eq: 0.13 | |
+--------------------+-----------------------+-----------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 2292000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -1581000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.3605
Average Volume: 596659.86
30-Day High: 1.09
30-Day Low: 0.3605

[Detailed Financials: Q3 2024]
- Total Assets: $5,615,000.0
- Total Liabilities: $4,128,000.0
- Total Equity: $1,487,000.0
- Current Assets: $5,338,000.0
- Current Liabilities: $4,025,000.0

[Income Statement: Q3 2024]
- Revenue: $2,292,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -3.11

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $0

[Detailed Financials: Q2 2024]
- Total Assets: $6,393,000.0
- Total Liabilities: $3,358,000.0
- Total Equity: $3,035,000.0
- Current Assets: $6,087,000.0
- Current Liabilities: $3,201,000.0

[Income Statement: Q2 2024]
- Revenue: $1,965,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.06

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $2,072,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

RSLS_OUT_19 [2025-04-01 05:38:54 -0400] 676 Bytes | 167 tokens | Cum: 4981 tkns (62.26% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

RSLS_IN_21 [2025-04-01 05:38:54 -0400] 126 Bytes | 29 tokens | Cum: 5090 tkns (63.62% of 8k)
==========================================================================

====================================
[2025-04-01 05:38:54] # Analysis Completed
Elapsed Time: 34.71 seconds